Post-partum depression – prevention, diagnosis and therapeutic approach

Medic ro ◽  
2021 ◽  
Vol 1 (139) ◽  
pp. 50
Author(s):  
Roxana Anamaria Viţelariu ◽  
Diana Vulea ◽  
Remus Şipoş
Keyword(s):  
Therapeutic Approach ◽  
Post Partum ◽  
Depression Prevention ◽  
Post Partum Depression

scholarly journals 208. Post partum depression: Prevention by diet and psychotherapy

2018 ◽  
Vol 9 (2) ◽  
pp. S24
Author(s):  
K. Vandana Vasudevan ◽  
Hemavathi ◽  
Anjali
Keyword(s):  
Post Partum ◽  
Depression Prevention ◽  
Post Partum Depression

scholarly journals Post-partum Depression-It’s Time to Pay Maximum Attention

2018 ◽  
Vol 04 (01) ◽  
Author(s):  
Ibrahim Abdul Rahman ◽  
Uzair Yaqoob ◽  
Tariq Ali Bhatti
Keyword(s):  
Post Partum ◽  
Post Partum Depression

scholarly journals Controlled trial of the short- and long-term effect of psychological treatment of post-partum depression

2003 ◽  
Vol 182 (5) ◽  
pp. 412-419 ◽  
Author(s):  
Peter J. Cooper ◽  
Lynne Murray ◽  
Anji Wilson ◽  
Helena Romaniuk
Keyword(s):  
Primary Care ◽  
Postnatal Depression ◽  
Post Partum ◽  
Psychodynamic Therapy ◽  
Term Effect ◽  
Short Term ◽  
Post Partum Depression ◽  
Maternal Mood ◽  
Long Term Effect

BackgroundPsychological interventions for postnatal depression can be beneficial in the short term but their longer-term impact is unknown.AimsTo evaluate the long-term effect on maternal mood of three psychological treatments in relation to routine primary care.MethodWomen with post-partum depression (n=193) were assigned randomly to one of four conditions: routine primary care, non-directive counselling, cognitive–behavioural therapy or psychodynamic therapy. They were assessed immediately after the treatment phase (at 4.5 months) and at 9, 18 and 60 months post-partum.ResultsCompared with the control, all three treatments had a significant impact at 4.5 months on maternal mood (Edinburgh Postnatal Depression Scale, EPDS). Only psychodynamic therapy produced a rate of reduction in depression (Structured Clinical Interview for DSM–III–R) significantly superior to that of the control. The benefit of treatment was no longer apparent by 9 months post-partum. Treatment did not reduce subsequent episodes of post-partum depression.ConclusionsPsychological intervention for post-partum depression improves maternal mood (EPDS) in the short term. However, this benefit is not superior to spontaneous remission in the long term.

Safety and Efficacy of Vortioxetine in the Treatment of Post-partum Depression: a Case Report

2015 ◽  
Vol 30 ◽  
pp. 1933
Author(s):  
K. Pavlovs ◽  
L. Berze ◽  
E. Rancans ◽  
P. Andzans
Keyword(s):  
Case Report ◽  
Post Partum ◽  
Safety And Efficacy ◽  
Post Partum Depression

Post-partum hemorrhage complicated by reverse-Takotsubo cardiogenic shock; a novel therapeutic approach

2017 ◽  
Vol 35 (6) ◽  
pp. 935.e1-935.e3 ◽  
Author(s):  
John Papanikolaou ◽  
Demosthenes Makris ◽  
Vasiliki Tsolaki ◽  
Konstantinos Spathoulas ◽  
Epaminondas Zakynthinos
Keyword(s):  
Cardiogenic Shock ◽  
Therapeutic Approach ◽  
Post Partum ◽  
Post Partum Hemorrhage ◽  
Novel Therapeutic

scholarly journals Treatment of post-partum depression: a review of clinical, psychological and pharmacological options

2010 ◽  
pp. 1 ◽  
Author(s):  
Kristin Leight ◽  
Fitelson ◽  
Sarah Kim ◽  
Allison Baker
Keyword(s):  
Post Partum ◽  
Post Partum Depression

scholarly journals Allopregnanolone mediates affective switching through modulation of oscillatory states in the basolateral amygdala

2021 ◽  
Author(s):  
Pantelis Antonoudiou ◽  
Phillip LW Colmers ◽  
Najah L Walton ◽  
Grant L Weiss ◽  
Anne C Smith ◽  
...  
Keyword(s):  
Basolateral Amygdala ◽  
Post Partum ◽  
Critical Role ◽  
Behavioral Outcomes ◽  
Theta Oscillations ◽  
Allosteric Modulators ◽  
Post Partum Depression ◽  
Antidepressant Effects ◽  
Behavioral States ◽  
Network States

AbstractBrexanolone (allopregnanolone), was recently approved by the FDA for the treatment of post-partum depression, demonstrating long-lasting antidepressant effects. Despite our understanding of the mechanism of action of neurosteroids as positive allosteric modulators (PAMs) of GABAa receptors, we still do not fully understand how allopregnanolone exerts these persistent antidepressant effects. Here, we demonstrate that allopregnanolone and similar synthetic neuroactive steroid analogs, SGE-516 (tool-compound) and zuranolone (SAGE-217, investigational-compound), are capable of modulating oscillatory states across species, which we propose may contribute to long-lasting changes in behavioral states. We identified a critical role for interneurons in generating oscillations in the basolateral amygdala (BLA) and a role for delta-containing GABAaRs in mediating the ability of neurosteroids to modulate network and behavioral states. Actions of allopregnanolone in the BLA is sufficient to alter behavioral states and enhance BLA high-theta oscillations (6-12Hz) through delta-containing GABAa receptors, a mechanism distinct from other GABAa PAMs, such as benzodiazepines. Moreover, treatment with the allopregnanolone analog SGE-516 induces long-lasting protection from chronic stress-induced disruption of network states, which correlates with improved behavioral outcomes. Our findings demonstrate a novel molecular and cellular mechanism mediating the well-established anxiolytic and antidepressant effects of neuroactive steroids.

Sign in / Sign up

Export Citation Format

Share Document